Ocular delivery of Amphotericin B: current challenges and future perspectives.

Velmurugan Kailasam, Samhita Sai Veda Koduganti, Oindrilla Dasgupta, Prashant Garg, Jayabalan Nirmal
{"title":"Ocular delivery of Amphotericin B: current challenges and future perspectives.","authors":"Velmurugan Kailasam, Samhita Sai Veda Koduganti, Oindrilla Dasgupta, Prashant Garg, Jayabalan Nirmal","doi":"10.1080/17425247.2024.2420750","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Amphotericin B is a polyene antibiotic that is used as an off-label eye drop to treat fungal keratitis. Poor solubility, permeability and high susceptibility to hydrolytic degradation make it challenging to formulate a drug delivery system. Despite its drawbacks, it is a potent antifungal drug against Candida and other fungal species. However, it has not been explored much in ocular drug delivery. Hence, this review brings into focus the potential and increasing significance of Amphotericin B in ocular drug delivery.</p><p><strong>Areas covered: </strong>In this review, we have systematically summarized the use of Amphotericin B in ocular diseases, the various formulation challenges for Amphotericin B, along with its off-label ocular usage, and stability concerns. The degradation mechanism of Amphotericin B in different conditions was discussed in this article as well.</p><p><strong>Expert opinion: </strong>In the last few decades, several nanocarriers have been explored to improve the formulation challenges associated with Amphotericin B. Also, due to insufficient clinical studies and unknown toxicity profile, there is no US Food and Drug Administration (FDA) approved Amphotericin B formulation for ocular drug delivery. This review aims to offer thorough information about Amphotericin B in ocular drug delivery.</p>","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1-13"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert opinion on drug delivery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17425247.2024.2420750","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Amphotericin B is a polyene antibiotic that is used as an off-label eye drop to treat fungal keratitis. Poor solubility, permeability and high susceptibility to hydrolytic degradation make it challenging to formulate a drug delivery system. Despite its drawbacks, it is a potent antifungal drug against Candida and other fungal species. However, it has not been explored much in ocular drug delivery. Hence, this review brings into focus the potential and increasing significance of Amphotericin B in ocular drug delivery.

Areas covered: In this review, we have systematically summarized the use of Amphotericin B in ocular diseases, the various formulation challenges for Amphotericin B, along with its off-label ocular usage, and stability concerns. The degradation mechanism of Amphotericin B in different conditions was discussed in this article as well.

Expert opinion: In the last few decades, several nanocarriers have been explored to improve the formulation challenges associated with Amphotericin B. Also, due to insufficient clinical studies and unknown toxicity profile, there is no US Food and Drug Administration (FDA) approved Amphotericin B formulation for ocular drug delivery. This review aims to offer thorough information about Amphotericin B in ocular drug delivery.

两性霉素 B 的眼部给药:当前挑战与未来展望。
简介两性霉素 B 是一种多烯类抗生素,被用作治疗真菌性角膜炎的非处方眼药水。两性霉素 B 溶解性、渗透性差,极易水解降解,因此配制给药系统具有挑战性。尽管存在这些缺点,但它仍是一种有效的抗真菌药物,可用于治疗念珠菌和其他真菌。然而,在眼部给药方面,对它的研究还不多。因此,本综述聚焦两性霉素 B 在眼部给药方面的潜力和日益重要的意义:在这篇综述中,我们系统地总结了两性霉素 B 在眼部疾病中的应用、两性霉素 B 的各种制剂挑战、标示外眼部用药以及稳定性问题。本文还讨论了两性霉素 B 在不同条件下的降解机制:在过去的几十年里,人们探索了多种纳米载体,以改善两性霉素 B 的制剂难题。此外,由于临床研究不足和毒性情况不明,美国食品和药物管理局(FDA)尚未批准用于眼部给药的两性霉素 B 制剂。本综述旨在提供有关两性霉素 B 用于眼部给药的全面信息。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信